Amino acid transporter SLC38A3 mediates bone cancer pain in rats via the PI3K/AKT/TRPV1 signaling pathway
Molecular Pain · 2025
DOI: 10.1177/17448069251395641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, 2025. Verfasst von Yu-Na Cheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the First Affiliated Hospital of Henan University, Kaifeng, China. Hauptthemen laut MEDLINE: TRPV Cation Channels, Cancer Pain, Signal Transduction, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, Key projects of Henan Science and Technology Department, national natural science foundation of china.
Abstract (Originalsprache)
Bone cancer pain (BCP), one of the most intractable symptoms in patients with cancer, remains poorly understood and lacks effective therapeutic interventions. In this study, we employed an established rat model of BCP induced by intratibial injection of MRMT-1 mammary carcinoma cells. Transcriptomic profiling of the L4-L6 dorsal root ganglia (DRGs) revealed an upregulation of the amino acid transporter SLC38A3. This finding was further confirmed by time-dependent increases in both its mRNA and protein levels. Immunofluorescence co-localization indicated that SLC38A3 was expressed in NF200-, CGRP-, and IB4-positive neurons within the L4-L6 DRGs, and its expression was upregulated in the BCP model. Concomitantly, the transient receptor potential vanilloid 1 (TRPV1) expression in BCP rat DRGs was dynamically upregulated at both the mRNA and protein levels, aligning temporally with pain hypersensitivity. Lentivirus-mediated overexpression or knockdown of SLC38A3 in the DRGs led to a corresponding upregulation or downregulation of TRPV1-expression. Activation of the PI3K/AKT signaling pathway corresponds with BCP-related pain behaviors and expression patterns of SLC38A3 and TRPV1. Bexarotene alleviates BCP in rats by suppressing the aberrant overexpression of SLC38A3, thereby blocking the PI3K/AKT signaling pathway-mediated upregulation of TRPV1. These findings indicate that SLC38A3, through its downstream PI3K/AKT-TRPV1 axis, may serve as a potential molecular mechanism for analgesia in BCP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, the First Affiliated Hospital of Henan University, Kaifeng, China.
- Institute of Chemical Biology, School of Pharmacy, Henan University, Kaifeng, China.
- School of Stomatology, Henan University, Kaifeng, Henan, China.
ORCID-Profile: Dong Fang
Förderung
- National Key R&D Program of China
- Key projects of Henan Science and Technology Department
- national natural science foundation of china
- science and technology department of henan province
- Educational Commission of Henan Province
Zitieren
APA
Cheng, Y. N., Zhang, M. Z., Xie, C. Q., Li, Z. Q., Ge, Y. F., Jin, Z. H., Luo, Z. H., Zheng, C. Y., Chen, L., Fang, D., Niu, C. G., & He, J. J. (2025). Amino acid transporter SLC38A3 mediates bone cancer pain in rats via the PI3K/AKT/TRPV1 signaling pathway. Molecular Pain. https://doi.org/10.1177/17448069251395641
Vancouver
Cheng YN, Zhang MZ, Xie CQ, Li ZQ, Ge YF, Jin ZH, et al. Amino acid transporter SLC38A3 mediates bone cancer pain in rats via the PI3K/AKT/TRPV1 signaling pathway. Molecular Pain. 2025. doi:10.1177/17448069251395641
BibTeX
@article{Cheng2025,
author = {Cheng, Yu-Na and Zhang, Ming-Zhu and Xie, Cui-Qing and Li, Zhi-Qi and Ge, You-Feng and Jin, Zhao-Hui and Luo, Zhi-Hua and Zheng, Chen-Yang and Chen, Liang and Fang, Dong and Niu, Chen-Guang and He, Jin-Jin},
title = {Amino acid transporter SLC38A3 mediates bone cancer pain in rats via the PI3K/AKT/TRPV1 signaling pathway},
journal = {Molecular Pain},
year = {2025},
doi = {10.1177/17448069251395641}
}
EUVIMED